Glaceum Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Private

  • Employees
  • 21

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $2.46M

  • Investors
  • 5

Glaceum General Information

Description

Developer of metabolic syndrome drug intended to create holistic cures for diverse diseases. The company specializes in treating various ailments such as obesity, diabetes, and fatty liver by targeting mitochondria, a central organelle responsible for producing energy and synthesizing key inflammation-related molecules, enabling patients to reduce chronic inflammation at a cellular level.

Contact Information

Website
www.glaceum.com
Formerly Known As
Eroom Medichem
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 906, Innoplex 3-dong, 304 Sinwon-ro
  • Suwon, Gyeonggi 16675
  • South Korea
+82
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Vertical(s)
Life Sciences
Corporate Office
  • 906, Innoplex 3-dong, 304 Sinwon-ro
  • Suwon, Gyeonggi 16675
  • South Korea
+82

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Glaceum Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC 14-Apr-2022 $2.46M Completed Clinical Trials - Phase 2
5. Later Stage VC (Series E) 01-Nov-2019 Completed Clinical Trials - Phase 1
4. Later Stage VC (Series D) 16-Apr-2019 Completed Clinical Trials - Phase 1
3. Later Stage VC (Series C) 01-Sep-2018 Completed Clinical Trials - Phase 1
2. Early Stage VC 12-Oct-2016 $2.69M $5.69M Completed Clinical Trials - Phase 1
1. Seed Round 01-May-2015 $3M $3M Completed Clinical Trials - Phase 1
To view Glaceum’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Glaceum Patents

  • 89

    Total Documents Applications and Grants

  • Total Patents Families

  • 59

    Granted

  • 16

    Pending

  • Expiring in next 12 mo

Glaceum Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4717265-A1 Pharmaceutical composition for preventing or treating degenerative osteoarthritis Pending 12-Jan-2023
US-20260216123-A1 Pharmaceutical composition for preventing or treating degenerative osteoarthritis Pending 12-Jan-2023
WO-2024151017-A1 Pharmaceutical composition for preventing or treating degenerative osteoarthritis Inactive 12-Jan-2023
WO-2024151017-A8 Pharmaceutical composition for preventing or treating degenerative osteoarthritis Inactive 12-Jan-2023
US-20250250279-A1 Method for synthesizing 3-phenyl-2,3,4,8,9,10-hexahydropyrano[2,3-f]chromene derivatives Pending 12-Apr-2022 C07D493/04
To view Glaceum’s complete patent history, request access »

Glaceum Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Glaceum Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds
Daewon Pharmaceutical Corporation Minority
J Curve Investment Venture Capital Minority
A Ventures Venture Capital Minority
Yukyung PSG Asset Management Asset Manager Minority
Quad Asset Management Asset Manager Minority
To view Glaceum’s complete investors history, request access »

Ready to get started?

Request a free trial

Glaceum FAQs

  • When was Glaceum founded?

    Glaceum was founded in 2014.

  • Where is Glaceum headquartered?

    Glaceum is headquartered in Suwon, South Korea.

  • What is the size of Glaceum?

    Glaceum has 21 total employees.

  • What industry is Glaceum in?

    Glaceum’s primary industry is Drug Discovery.

  • Is Glaceum a private or public company?

    Glaceum is a Private company.

  • What is Glaceum’s current revenue?

    The current revenue for Glaceum is .

  • How much funding has Glaceum raised over time?

    Glaceum has raised $27.4M.

  • Who are Glaceum’s investors?

    Daewon Pharmaceutical, J Curve Investment, A Ventures, Yukyung PSG Asset Management, and Quad Asset Management have invested in Glaceum.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process